|
|
|
|
|
|
|
14.08.25 - 13:33
|
Cassava Reports Q2 2025 Financials Results and Provides Business Update (GlobeNewswire EN)
|
|
|
AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the second quarter ended June 30, 2025 and provided a business update....
|
|
|
07.08.25 - 13:33
|
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer (GlobeNewswire EN)
|
|
|
AUSTIN, Texas, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced the appointment of Dr. Joseph Hulihan as Chief Medical Officer (CMO). Dr. Hulihan will devote approximately half of his professional time to Cassava, advising on the clinical development of simufilam, Cassava's investigational candidate for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy....
|
|
|
|
|
|
|
21.04.25 - 22:33
|
Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development (GlobeNewswire EN)
|
|
|
AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system (CNS) disorders such as tuberous sclerosis complex (TSC)-related epilepsy, today announced the retirement of James W. Kupiec, MD, Chief Medical Officer, effective May 9, 2025. The Company also appointed Jack Moore, PhD, as Senior Vice President, Clinical Development, reporting to Rick Barry, Chief Executive Officer....
|
|
|
|
|
|
|
|
|
25.03.25 - 15:42
|
XFRA : PX91: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
CASSAVA SCIENCES DL-,001 PX91 US14817C1071
AB/FROM ONWARDS 25.03.2025 15:33 CET...
|
|
|
25.03.25 - 13:36
|
XFRA : PX91: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
CASSAVA SCIENCES DL-,001 PX91 US14817C1071 BAW/UFN...
|
|
|
|
|
25.03.25 - 13:09
|
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data (GlobeNewswire EN)
|
|
|
AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing a novel, investigational treatment for central nervous system disorders, including Alzheimer's disease (AD) dementia and tuberous sclerosis complex (TSC)-related epilepsy, today shared topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate AD....
|
|
|
|
|
|
|
03.03.25 - 13:33
|
Cassava Sciences Reports 2024 Financial Results and Provides Business Update (GlobeNewswire EN)
|
|
|
AUSTIN, Texas, March 03, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, including Alzheimer's disease and tuberous sclerosis complex (TSC)-related seizures, today reported financial results for the year ended December 31, 2024 and provided a business update....
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
